Postmarketing safety profile of brexanolone: a pharmacovigilance analysis based on FDA Adverse Event Reporting System (FAERS)
Crossref DOI link: https://doi.org/10.1007/s00737-023-01378-1
Published Online: 2023-10-13
Published Print: 2024-02
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Zhang, Meilian
Xie, Wenhuo
Li, Jianbin
Zheng, Jiaping
Zhou, Yu http://orcid.org/0000-0003-1942-3073
Text and Data Mining valid from 2023-10-13
Version of Record valid from 2023-10-13
Article History
Received: 25 June 2023
Accepted: 3 October 2023
First Online: 13 October 2023
Declarations
:
: The authors declare no competing interests.